Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SLGL with free AI briefings, catalyst countdowns, and dilution alerts.

SLGL · Sol-Gel Technologies Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$47.9M Cash on Hand
67.3mo Cash Runway
Follow SLGL by email Get an email when SLGL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SLGL, unsubscribe in one click. Privacy

📣 What SLGL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
S6G5T-8 Acne Vulgaris Phase 3 · NCT03761810 Completed
Patidegib Topical Gel Gorlin Syndrome Phase 3 · NCT06050122 Completed
Patidegib Topical Gel, 2% Basal Cell Nevus Syndrome Phase 3 · NCT04308395 Terminated
5-FU Cream Actinic Keratosis (AK) Phase 3 · NCT03727074 Completed
S6G5T-3 Acne Vulgaris Phase 3 · NCT03761810 Completed
S5G4T-1 Papulopustular Rosacea Phase 3 · NCT03564145 Terminated
S5G4T-2 Papulopustular Rosacea Phase 3 · NCT03564119 Completed
S2G6T-3 Tinea Pedis Phase 2 · NCT02842021 Terminated
S6G5T-7 Acne Vulgaris Phase 2 · NCT02661958 Completed
S6G5T-6 Acne Vulgaris Phase 2 · NCT02661958 Completed
S6G5T-5 Acne Vulgaris Phase 2 · NCT02661958 Completed
S6G5T-1 Acne Vulgaris Phase 2 · NCT02661958 Completed
S2G6T-4 Tinea Pedis Phase 2 · NCT02842021 Terminated
S2G6T-2 Tinea Pedis Phase 2 · NCT02842021 Terminated
S2G6T-1 Tinea Pedis Phase 2 · NCT02842021 Terminated
DER 45 EV Rosacea Phase 2 · NCT00940992 Completed

Also used in these trials (approved or third-party drugs, not SLGL's own candidates): Fluorouracil.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SLGL holds $47.9M in cash and short-term investments and burns about $2.1M/quarter from operations, an estimated runway of 67.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLGL files for a raise →

👥 Who Owns SLGL

Insiders 89.6% Institutions (29 holders) 10.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Moshe Arkin
Chairman of Board and CEO, Director, 10%
Insider 1,950,113 69.99% 2026-03-25
Opaleye Management Inc.
10% owner
Insider 540,000 19.38% 2026-09-30
Great Point Partners, LLC Institution (13G, 5%+) 274,363 9.85% 2026-03-24
Trails Edge Capital Partners, LP Institution (13G, 5%+) 166,473 5.98% 2026-10-20
Ran Gottfried
Director
Insider 1,550 0.06% 2026-03-18
Michael Glezin
Chief Business Officer
Insider 1,500 0.05% 2026-03-18
Ofer Toledano
VP Research & Dev.
Insider 1,461 0.05% 2026-03-18
Eyal Ben-Or
Chief Financial Officer
Insider 1,000 0.04% 2026-03-18

Share count 2,786,158 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SLGL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLGL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.